90 related articles for article (PubMed ID: 15524424)
1. [Sibutramine administration in polycystic ovary syndrome treatment].
Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Jochemczyk-Banek U; Banaś M; Zurakowski A
Ginekol Pol; 2004 Jun; 75(6):470-4. PubMed ID: 15524424
[TBL] [Abstract][Full Text] [Related]
2. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
Georgopoulos NA; Katsikis I; Florakis D; Panidis D; Kandarakis ED
Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719
[No Abstract] [Full Text] [Related]
3. Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
Vosnakis C; Georgopoulos NA; Armeni AK; Papadakis E; Roupas ND; Katsikis I; Panidis D
Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):185-9. PubMed ID: 22579228
[TBL] [Abstract][Full Text] [Related]
4. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
[TBL] [Abstract][Full Text] [Related]
5. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Lindholm Å; Bixo M; Björn I; Wölner-Hanssen P; Eliasson M; Larsson A; Johnson O; Poromaa IS
Fertil Steril; 2008 May; 89(5):1221-1228. PubMed ID: 17603048
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
8. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease.
Karabacak IY; Karabacak O; Törüner FB; Akdemir O; Arslan M
Gynecol Endocrinol; 2004 Oct; 19(4):196-201. PubMed ID: 15724802
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Scheen AJ
Rev Med Liege; 2001 Jan; 56(1):56-8. PubMed ID: 11256141
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
11. The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Slovacek L; Pavlik V; Slovackova B
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):e43-4. PubMed ID: 18676135
[No Abstract] [Full Text] [Related]
12. Sibutramine for obesity.
Med Lett Drugs Ther; 1998 Mar; 40(1022):32. PubMed ID: 9529518
[No Abstract] [Full Text] [Related]
13. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
von Haehling S; Lainscak M; Anker SD
Eur Heart J; 2007 Dec; 28(23):2830-1. PubMed ID: 17984134
[No Abstract] [Full Text] [Related]
14. Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Lazurova I; Dravecka I; Kraus V; Petrovicova J
Bratisl Lek Listy; 2004; 105(5-6):207-10. PubMed ID: 15535111
[TBL] [Abstract][Full Text] [Related]
15. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of sibutramine.
Lieberman JA
J Fam Pract; 2002 Oct; 51(10):863; author reply 863, 867. PubMed ID: 12401157
[No Abstract] [Full Text] [Related]
17. [Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity].
Vlasova IuIu; Ametov AS
Ter Arkh; 2010; 82(8):44-7. PubMed ID: 20873245
[TBL] [Abstract][Full Text] [Related]
18. Sibutramine: its mode of action and efficacy.
Finer N
Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S29-33. PubMed ID: 12457297
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sibutramine in the treatment of obesity.
Warren E; Brennan A; Akehurst R
Med Decis Making; 2004; 24(1):9-19. PubMed ID: 15005950
[TBL] [Abstract][Full Text] [Related]
20. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
Astrup A
Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
